Neurology · 2018 · 25 citations · 18 references
MedicinePharmacotherapyUrologyPain ManagementUrodynamicsVoiding DysfunctionBladder Function AssessmentDetrusor UnderactivityMultiple SclerosisUrinary IncontinenceUrinary Incontinence AssessmentUrinary Retention ManagementDetrusor Overactivity ManagementIntravesical OnabotulinumtoxinaMultiple Sclerosis TherapyMultiple Sclerosis-related Bladder DysfunctionMultiple Sclerosis-related Voiding DysfunctionOnabotulinumtoxina TherapySerious Adverse EventsUrinary Symptoms Management
<h3>Objective</h3> To evaluate the efficacy and safety of onabotulinumtoxinA 100 U in noncatheterizing patients with multiple sclerosis (MS) with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO). <h3>Methods</h3> In this randomized, double-blind phase III study, patients received onabotulinumtoxinA 100 U (n = 66) or placebo (n = 78) as intradetrusor injections via cystoscopy. Assessments included changes from baseline in urinary symptoms, urodynamics, and Incontinence–Quality of Life (I-QOL) total score. Adverse events (AEs) were assessed, including initiation of clean intermittent catheterization (CIC) due to urinary retention. <h3>Results</h3> OnabotulinumtoxinA vs placebo significantly reduced UI at week 6 (−3.3 episodes/day vs −1.1 episodes/day, <i>p</i> < 0.001; primary endpoint). Significantly greater proportions of onabotulinumtoxinA-treated patients achieved 100% UI reduction (53.0% vs 10.3%, <i>p</i> < 0.001). Significant improvements in urodynamics (<i>p</i> < 0.01) were observed with onabotulinumtoxinA. Improvements in I-QOL score were significantly greater with onabotulinumtoxinA (40.4 vs 9.9, <i>p</i> < 0.001) and ≈3 times the minimally important difference (+11 points). The most common AE was urinary tract infection (25.8%). CIC rates were 15.2% for onabotulinumtoxinA and 2.6% for placebo. <h3>Conclusion</h3> In noncatheterizing patients with MS, onabotulinumtoxinA 100 U significantly improved UI and quality of life with lower CIC rates than previously reported with onabotulinumtoxinA 200 U. <h3>ClinicalTrials.gov identifier:</h3> NCT01600716. <h3>Classification of evidence</h3> This study provides Class I evidence that compared with placebo, 100 U onabotulinumtoxinA intradetrusor injections significantly reduce UI and improve quality of life in noncatheterizing patients with MS and NDO.
18
Rating neurologic impairment in multiple sclerosis
John F. Kurtzke · Neurology · 1983 · 14.9K citations
EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction
M. Stöhrer, Bertil Blok, David Castro‐Díaz et al. · European Urology · 2009 · 565 citations
Francisco Cruz, Sender Herschorn, Philip J. Aliotta et al. · European Urology · 2011 · 471 citations
Medicine, Pharmacotherapy, Urology +16
Christopher R. Chapple, Karl‐Dietrich Sievert, Scott MacDiarmid et al. · European Urology · 2013 · 408 citations
Medicine, Pharmacotherapy, Urology +16